Glossary
This glossary provides brief explanations of terms used in the Ontario Public Drug Programs web pages. To access a term definition, select the appropriate letter from the alphabet below.
| Effectiveness |
The way we measure the benefit resulting from an intervention for a health problem under usual conditions of clinical care for a particular group. This form of evaluation considers both the effect of an intervention and its acceptance by those to whom it is offered, answering the question, "Does the practice do more good than harm to the people to whom it is offered?" |
| Efficacy |
A measure of the benefit that results from intervening for a given health problem under ideal conditions. It answers the question, "Does the practice do more good than harm to people who fully comply with the recommendations?" |
| Endpoint |
The overall outcome that the protocol is designed to evaluate. Common endpoints include severe toxicity, disease progression, or death. |
| EO |
See Executive Officer |
| Evidence |
Information upon which a decision or guidance is based. Evidence is obtained from a range of sources including randomized controlled trials, observational studies, and expert opinion (of clinical professionals and/or patients).
|
| Exceptional Access mechanism |
The ministry's Exceptional Access/ Individual Clinical Review (ICR) mechanism is a comprehensive approach to help patients access medications where formulary drugs were ineffective, not tolerated or no alternative was available on the Ontario Drug Benefit (ODB) Formulary/Comparative Drug Index (Formulary). The mechanism ensures appropriate prescribing based on cost-effective, evidence-based care.
The current ICR mechanism is being changed to a new, more streamlined Exceptional Access mechanism that will handle requests for drugs that are not funded as conditional listings in a way that minimizes the impact on prescribers and make it more transparent to prescribers and patients.
|
| Executive Officer (EO) |
The Executive Officer (EO) of the Ontario Public Drug Programs is responsible for creating a new enterprise to manage all activities dealing with the publicly-funded Ontario Drug Benefit. Specifically, the EO keeps, maintains and publishes the Formulary; decides on funding/drug coverage through Ontario’s drug programs and the Exceptional Access mechanism; decides which products are designated interchangeable, negotiates agreements with manufacturers of drug products, and provides payments under the Ontario public drug programs.
Performing the functions of Chief Executive Officer, the EO ensures efficient organization through planning, execution, issues’ management, program review and performance measurement processes.
|
|
Text Only Version
